It's a nice day for shareholders of Kosan Biosciences Inc. (NASDAQ: KOSN), which is a cancer therapeutics company. The stock price is up 230% to $5.44.

That is, Bristol-Myers Squibb Company (NYSE: BMY) has agreed to purchase Kosan for $190 million. The transaction will be structured as a cash tender offer.

Founded in 1995, Kosan has two key anticancer agents in clinical development -- heat shock protein 90 (Hsp90) inhibitors and epothilones. Some of the treatments include multiple myeloma and metastatic breast cancer.

Basically, Kosan didn't have the wherewithal to take these drugs to market (after all, the capital markets have been fairly skittish lately). So, a partnership with Bristol-Myers does make a lot of sense. Keep in mind that the company has a large oncology business.

Interestingly enough, the parties also announced a separate licensing agreement to market Kosan's epothilone compounds. The deal involves an upfront $25 million payment as well as milestone payments.

Although, the agreement is only triggered if the merger falls through. In other words, Kosan has a nice backstop on the transaction.

Tom Taulli is the author of various books, including The Complete M&A Handbook and The Edgar Online Guide to Decoding Financial Statements. He also operates MergerBook.com.

MOST NOTEWORTHY: The U.S. clean energy sector, MGI Pharma, Apple and Kosan Biosciences were today's noteworthy initiations:

• Morgan Stanley initiated the U.S. clean energy sector with an Attractive view. The analyst assumed coverage of First Solar (NASDAQ: FSLR), Fuel Tech (NASDAQ: FTEK) and SunPower Corporation (NASDAQ: SPWR) with Overweight ratings and EnerNOC, Inc (NASDAQ: ENOC) with an Underweight rating.
  
• Banc of America started shares of MGI Pharma (NASDAQ: MOGN) with a Buy rating and $45 target, as they expect sales growth in 2008 to be driven by Aquavan, which they view as an underappreciated asset, and potential survival data for Dacogen.
  
• Soleil believes Apple (NASDAQ: AAPL) could nearly double its PC market share to between 5.5% and 6% over the next five years. The firm started shares with a Buy rating and $200 target.
  
• Roth Capital initiated Kosan Biosciences (NASDAQ: KOSN) with a Buy rating and $10 target, as they are positive on the company's Hsp90 program and expect an NDA filing as early as 2009 in the relapsed-refractory settings.

OTHER INITIATIONS:

• KeyBanc Capital initiated CastlePoint Holdings (NASDAQ: CPHL) with a Buy rating and $16 target.
  
• Time Warner Telecom (NASDAQ: TWTC) was started at Cowen with an Outperform rating.
  
• Jefferies resumed coverage of Windstream (WIN) with a Hold rating and $16 target and Embarq Corporation (NYSE: EQ) with a Buy rating and $68 target.